As far as IBD was concerned, three datasets (GSE16879, GSE92415, GSE23597) assessed patients with ulcerative colitis (UC) as responders to anti-TNFα therapy with the Mayo scores, where a decrease of Mayo subscores of at least three points by 30%, with the exception of Arijs et al. where a decrease in Mayo endoscopic subscores considered patients as responders [23]. The gene discussed is TNF; the disease is ulcerative colitis.